New Trial Combines Two Immunotherapies Against Melanoma (Yervoy & Prophage) | Melanoma Dispatch |

Will the FDA-approved immune system booster Yervoy (ipilimumab) work better when combined with an experimental melanoma vaccine? Researchers are about to find out ─ the combination will be tested in a phase II clinical trial of up to 25 people. Ipilimumab doesn’t work on its own in about 70% of people with melanomas. The vaccine, called Prophage, could sharpen immune system attacks because it’s made from people’s own tumors.